In yesterday’s Wall Street session, Gamida Cell Ltd (NASDAQ:GMDA) shares traded at $0.30, up 20.80% from the previous session.
As of this writing, 4 analysts cover Gamida Cell Ltd (NASDAQ:GMDA). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $2.00, we find $4.00. Given the previous closing price of $0.25, this indicates a potential upside of 1500.0 percent. GMDA stock price is now -63.33% away from the 50-day moving average and -77.57% away from the 200-day moving average. The market capitalization of the company currently stands at $40.06M.
There are 0 analysts who have given it a hold rating, whereas 4 have given it a buy rating. Brokers who have rated the stock have averaged $4.00 as their price target over the next twelve months.
With the price target of $11, Alliance Global Partners recently initiated with Buy rating for Gamida Cell Ltd (NASDAQ: GMDA).
A total of 15.06% of the company’s stock is owned by insiders.
Tuesday morning saw Gamida Cell Ltd (NASDAQ: GMDA) opened at $0.2511. During the past 12 months, Gamida Cell Ltd has had a low of $0.22 and a high of $2.51. As of last week, the company has a debt-to-equity ratio of 224.26, a current ratio of 3.32, and a quick ratio of 3.20. The fifty day moving average price for GMDA is $0.8244 and a two-hundred day moving average price translates $1.3469 for the stock.
The latest earnings results from Gamida Cell Ltd (NASDAQ: GMDA) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.01, beating analysts’ expectations of -$0.17 by 0.16. This compares to -$0.29 EPS in the same period last year. The net profit margin was -11434.03% and return on equity was -1103.79% for GMDA. For the current quarter, analysts expect GMDA to generate $1.06M in revenue.
Gamida Cell Ltd(GMDA) Company Profile
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company’s lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
